Re:Norepinephrine-mediated slow vasomotion drives glymphatic...
by AbstractH24 on Wednesday January 15, 2025 @11:55AM
(#42713500)
The other day, I asked Gemini for suggestions on "sunny places in Latin America to visit in January," it recommended Miami.
I'm done with it for another 6 months again.
Re:Norepinephrine-mediated slow vasomotion drives glymphatic...
by Aurornis on Wednesday January 15, 2025 @11:12AM
(#42712727)
> Went to look up Ambien's company's stock.
Ambien has been generic for a very long time. It's not an expensive drug.
It's also not even indicated for long-term nightly use. You can find stories online of people who get continuous prescriptions from their doctor, but doing so is a rare practice. Most doctors are nervous to prescribe any drug of this class right now. When they do, it's only for short-term or occasional use.
I don't think this is really a pitchforks-out moment against drug companies.
Re:Norepinephrine-mediated slow vasomotion drives glymphatic...
by habitue on Wednesday January 15, 2025 @11:13AM
(#42712749)
It's one study, on mice. This is the beginning of a long chain where more studies are done -> a consensus is formed -> doctors start to hear about the consensus and take it into account prescribing it
It could plausibly be 20 years before that plays out
> Cosette Pharmaceuticals is permanently closed, so there is no stock for the company.
> Cosette Pharmaceuticals was a pharmaceutical company that manufactured topical creams, ointments, oral liquids, and suppositories. They had facilities in New Jersey and North Carolina.
No, Google. They're just a private company.
Thanks, Google.
Beyond this, I can't imagine this drug will be something people will want to continue taking. It was already posited to not be good for Alzheimer's, and now they have a smoking gun for a plausible mechanism.